title: Does anti-HBV therapy benefit the prognosis of HBV-related hepatocellular carcinoma following hepatectomy?
abstract: The Hepatitis B virus (HBV) is an important etiological factor for hepatocarcinogenesis, because HBV DNA load and HBV reactivation are major risks that influence the long-term survival of hepatocellular carcinoma (HCC) patients who underwent hepatectomy and, thus, may cause postoperative liver function deterioration, tumor recurrence, and reduce patient's overall survival. However, anti-HBV therapy can suppress HBV replication, improve the remnant liver function, render patients better able to tolerate HCC treatments, and may even improve their prognosis. In this paper, an anti-HBV therapy that benefits the prognosis of HBV-related HCC following hepatectomy is reviewed.
authors.forename: Liang-He
authors.initials: LH
authors.lastname: Yu
authors.forename: Nan
authors.initials: N
authors.lastname: Li
authors.forename: Jie
authors.initials: J
authors.lastname: Shi
authors.forename: Wei-Xing
authors.initials: WX
authors.lastname: Guo
authors.forename: Meng-Chao
authors.initials: MC
authors.lastname: Wu
authors.forename: Shu-Qun
authors.initials: SQ
authors.lastname: Cheng
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000601:surgery / Q000821:virology; D006498:Hepatectomy / Q000401:mortality*; D006509:Hepatitis B / Q000188:drug therapy / Q000821:virology; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000601:surgery / Q000821:virology; D011379:Prognosis; D019562:Viral Load
chemical_list: D000998:Antiviral Agents